21-Mar-2024	Kazia Therapeutics licenses paxalisib to Sovargen for intractable seizures in rare central nervous system diseases

14-Mar-2024	Kazia announces presentation of new data at AACR Annual Meeting

21-Feb-2024	Kazia Therapeutics Reports Early Conclusion of Clinical Trial After Reaching Primary Endpoint

19-Jan-2024	Kazia Continues Board Renewal With Two New Appointments

15-Jan-2024	Resignation of Chief Financial Officer; Appointment of Principal Accounting Officer and Principal Financial Officer

2-Dec-2023	Kazia Therapeutics Announces $2 Million Registered Direct Offering

1-Dec-2023	Kazia AGM - Chairman's Address

1-Dec-2023	Kazia 2023 Annual General Meeting R&D and Clinical Overview

1-Dec-2023	Kazia AGM Meeting results

29-Nov-2023	Kazia Announces Non-binding Letter of Intent for the Proposed Granting of Rights to Develop and Commercialize Paxalisib Outside of Oncology

21-Nov-2023	Kazia Provides Overview Of Paxalisib Related Presentations from the Society Of Neuro-oncology 2023 Annual Meeting